| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 |
|---|---|---|---|---|---|---|---|---|
Revenue: | ||||||||
Revenue | ||||||||
44,674 | 54,579 | 35,427 | 6,155 | 14,079 | 25,421 | 20,181 | 340 | 882 |
Collaborative arrangement revenue | ||||||||
36,469 | 52,353 | 22,207 | 6,155 | 14,079 | 25,031 | 19,792 | - | 0 |
Research and license fees | ||||||||
- | - | - | - | - | 390 | 389 | 340 | 640 |
Grant revenue | ||||||||
- | - | - | - | - | - | - | - | 242 |
Operating expenses: | ||||||||
Research and development | ||||||||
582,413 | 448,589 | 273,040 | 204,775 | 134,038 | 62,574 | 31,002 | 17,210 | 11,409 |
Selling, general and administrative | ||||||||
271,362 | 174,129 | 93,550 | 65,119 | 46,209 | 23,227 | 14,126 | 6,846 | 4,615 |
Cost of royalty revenue | ||||||||
2,978 | 885 | 1,527 | - | - | - | - | - | - |
Change in fair value of contingent consideration | ||||||||
2,747 | 2,999 | -525 | 4,091 | 2,869 | 246 | - | - | - |
Total operating expenses | ||||||||
859,500 | 626,602 | 367,592 | 273,985 | 183,116 | 86,047 | 45,128 | 24,056 | 16,024 |
Loss from operations | ||||||||
-814,826 | -572,023 | -332,165 | -267,830 | -169,037 | -60,626 | -24,947 | -23,716 | -15,142 |
Interest income, net | ||||||||
34,761 | 14,624 | -2,001 | 3,782 | 1,591 | - | 29 | 5 | 5 |
Other expense, net | ||||||||
-10,088 | 1,961 | -1,267 | -71 | 723 | 120 | -403 | - | -456 |
Foreign currency gains (losses) | ||||||||
- | - | - | - | - | - | - | 13 | -100 |
Re-measurement of warrants | ||||||||
- | - | - | - | - | - | - | -28 | 361 |
Total other income (expense), net | ||||||||
- | - | - | - | - | - | -374 | 46 | - |
Loss before income taxes | ||||||||
-790,153 | -555,438 | -335,433 | -264,119 | -166,723 | -60,506 | -25,321 | -23,670 | - |
Income tax (expense) benefit | ||||||||
-500 | 200 | 200 | -612 | 60 | -11,797 | - | - | - |
Net loss | ||||||||
-789,608 | -555,625 | -335,643 | -263,507 | -166,783 | -48,709 | -25,321 | -23,670 | -15,598 |
Accretion and dividends on convertible preferred stock | ||||||||
- | - | - | - | - | - | - | 3,057 | 4,993 |
Gain on extinguishment of convertible preferred stock | ||||||||
- | - | - | - | - | - | - | -23,114 | 0 |
Net loss applicable to common stockholders | ||||||||
- | - | - | - | - | - | - | -3,613 | -20,591 |
Net loss per share - basic and diluted: | ||||||||
-14.31 | -10.68 | -7.71 | -7.07 | -4.81 | -1.83 | -2.02 | -13.79 | -171.59 |
Weighted-average number of common shares used in computing net loss per share - basic and diluted: | ||||||||
55,191 | 52,032 | 43,535 | 37,284 | 34,669 | 26,546 | 12,555 | 262 | 120 |
Other comprehensive (loss) income: | ||||||||
Other comprehensive (loss) income, net of tax expense of $0.0 million and $0.4 million for the three months ended March 31, 2020 and 2019, respectively | ||||||||
- | - | - | 1,142 | -2,220 | -71 | - | -1 | 1 |
Foreign currency translation adjustment | ||||||||
- | - | - | - | - | - | - | - | 72 |
Total other comprehensive (loss) income | ||||||||
1,734 | 578 | -3,056 | 1,142 | -2,220 | -71 | - | -1 | 73 |
Weighted-average number of common shares used in computing net (loss) income per share applicable to common stockholders: | ||||||||
Comprehensive loss | ||||||||
-787,874 | -555,047 | -338,699 | -262,365 | -169,003 | -48,780 | -25,321 | -23,671 | -15,525 |
Other comprehensive income (loss) tax expense | ||||||||
1,200 | 400 | 0 | - | - | - | - | - | - |
Royalty revenue | ||||||||
Revenue | ||||||||
8,205 | 2,226 | 13,220 | - | - | - | - | - | - |